Equibor SRL
The score of Equibor shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets -12 %
Accounts of the company itself (not consolidated).
The full file covers 7 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Equibor's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 25 Jun 2026
- Year ended 31 Dec 2024filed on 28 Jul 2025
- Year ended 31 Dec 2023filed on 05 Aug 2024
- Year ended 31 Dec 2022filed on 16 Jun 2023
- Year ended 31 Dec 2021filed on 08 Jul 2022
Equibor's financial analysis
- Solvency24.7%sector median: 46.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Equibor
Equibor's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0711.998.905
- VAT number
- BE0711998905
- Peppol
- Registered · 0208:0711998905 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 23 Oct 2018
- Registered office
- 7170 Manage
- Latest accounts
- 2025 · filed on 25 Jun 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
Equibor (SRL) has been based in Manage since 2018, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net profit of 26,934 € and equity of 276,354 €; its revenue is not published. Its solvency stands at 24.7%, below the median of its sector (46.9%).
Companies similar to Equibor
Companies in the same business, of comparable size and area, outside its group.
- GRNR Invest Manufacture of basic pharmaceutical products Zemst · balance sheet €2.26m
- Plant Bio Technologies Manufacture of basic pharmaceutical products Ghent · balance sheet €1.04m
- Pharma Chemicals France Manufacture of basic pharmaceutical products Braine-le-Château · balance sheet €1.08m
- Galenicap Manufacture of basic pharmaceutical products Ixelles · balance sheet €1.47m
- OLYS Pharma Manufacture of pharmaceutical preparations La Hulpe · balance sheet €1.03m
- XeroThera Europe Manufacture of basic pharmaceutical products Liège · balance sheet 820,359 €
- Takeair Manufacture of basic pharmaceutical products Oudenaarde · balance sheet €1.52m
- Groupe Tete Pharmaceutical Manufacture of basic pharmaceutical products Nivelles · balance sheet €1.15m
Frequently asked questions about Equibor
What is the revenue of Equibor?
Equibor files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Equibor?
In Belgium, the VAT number is the company number prefixed with BE: BE0711998905 for Equibor, if the company is VAT-registered. Its company number (CBE) is 0711.998.905.
Where is the registered office of Equibor?
According to the CBE register, the registered office of Equibor is in 7170 Manage.
What is the equity of Equibor?
At the close of the 2025 financial year, the equity of Equibor amounts to 276,354 €, a solvency of 24.7% of total assets.
Who manages Equibor?
The register lists 1 active mandates at Equibor. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Equibor
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →